Last updated on January 2019

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies


Brief description of study

This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

Clinical Study Identifier: NCT03453619

Contact Investigators or Research Sites near you

Start Over

Apellis Investigational Site

Wilmington, NC United States
  Connect »

Apellis Investigational Site

Alexandria, VA United States
  Connect »

Apellis Investigational Site

Stanford, CA United States
  Connect »

Apellis Investigational Site

Washington, WA United States
  Connect »

Apellis Investigational Site

Coral Gables, FL United States
  Connect »

Apellis Investigational Site

Takoma Park, MD United States
  Connect »

Apellis Investigational Site

Kansas City, MO United States
  Connect »

Apellis Investigational Site

Chesapeake, VA United States
  Connect »

Apellis Investigational Site

Wauwatosa, WI United States
  Connect »

Apellis Investigational Site

Louisville, KY United States
  Connect »

Apellis Investigational Site

Shreveport, LA United States
  Connect »

Apellis Investigational Site

Valhalla, NY United States
  Connect »

Apellis Investigational Site

Cincinnati, OH United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.